SEC Form 4 · accession 0001123292-26-001126
Bluejay Diagnostics, Inc. · BJDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas Clark Wurth
Director
Period of report
Aug 17, 2026
Accepted (ET)
Aug 18, 2026 · 4:16 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001704287
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.075 | Aug 17, 2026 | A | 100,000 | A | — | Aug 17, 2031 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.